



We claim:

1. A compound having the structural formula



- 5 or a pharmaceutically acceptable salt thereof, wherein

R is




$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  are independently selected from the group consisting of H, alkyl and alkoxyalkyl;

- 10  $R^6$  is H, alkyl, hydroxyalkyl or  $-\text{CH}_2\text{F}$ ;

$R^7$ ,  $R^8$  and  $R^9$  are independently selected from the group consisting of H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo and  $-\text{CF}_3$ ;

Z is  $R^{10}$ -aryl,  $R^{10}$ -heteroaryl or



- 15  $R^{10}$  is 1 to 5 substituents independently selected from the group consisting of hydrogen, alkyl, alkenyl, hydroxy, alkoxy, hydroxyalkyl, hydroxy-alkoxy, alkoxyalkyl, alkoxyalkoxy, alkoxy-alkoxy-alkyl-, (di-alkoxy)-alkyl, (hydroxy)-alkoxyalkyl,  $R^{15}$ -cycloalkyl,  $R^{15}$ -cycloalkylalkyl, cycloalkyl-oxy, cycloalkyl-O-alkoxy, alkyl- $\text{SO}_2$ -, alkyl- $\text{SO}$ -, halo, -CN, cyanoalkyl,  $-\text{CHF}_2$ ,  $-\text{CF}_3$ ,  $-\text{OCHF}_2$ ,  $-\text{OCF}_3$ ,  $-\text{C}(\text{O})\text{R}^{13}$ ,  
 20  $-\text{O-alkylene-C}(\text{O})\text{OR}^{13}$ ,  $-\text{C}(\text{O})\text{O-alkyl}$ ,  $-\text{N}(\text{R}^{11})(\text{R}^{12})$ ,  $\text{N}(\text{R}^{11})(\text{R}^{12})$ -alkyl,  $\text{N}(\text{R}^{11})(\text{R}^{12})$ -alkoxy,  $-\text{C}(\text{O})\text{N}(\text{R}^{13})(\text{R}^{16})$ ,  $\text{R}^{11}$ -heteroaryl,  $\text{R}^{15}$ -heterocycloalkyl,  $\text{R}^{15}$ -heterocycloalkyl-alkyl,  $\text{R}^{15}$ -heterocycloalkyl-alkoxy,  $\text{R}^{15}$ -heterocycloalkyl-oxy,  $\text{CF}_3$ -alkylene-O-alkyl,  $\text{CF}_3$ -hydroxyalkyl,  $(\text{CF}_3)(\text{hydroxy})\text{alkoxy}$ , cyano-alkoxy, -alkylene- $\text{C}(\text{O})$ -O-alkyl,  $-\text{SO}_2\text{-N}(\text{alkyl})_2$ , (cycloalkyl)hydroxyalkyl, (hydroxyalkyl)alkoxy, (dihydroxy)alkyl,  
 25 (dihydroxy)alkoxy,  $-\text{C}(=\text{NOR}^{17})$ -alkyl and  $-\text{C}(=\text{NOR}^{17})-\text{CF}_3$ ;

or two  $R^{10}$  groups on adjacent carbon ring atoms together form  $-\text{O}-\text{CH}_2-\text{O}-$ ,  $-\text{O}-(\text{CH}_2)_2-\text{O}-$ ,  $-\text{CH}_2-\text{O}-(\text{CH}_2)_2-\text{O}-$ ,  $-\text{O}-(\text{CH}_2)_2-$ ,  $-(\text{CH}_2)_3-\text{O}-$ ,  $-\text{O}-(\text{CH}_2)_3-\text{O}-$ ,  $-(\text{CH}_2)_3-$ ,

wherein the ring formed by the two  $R^{10}$  substituents and the ring carbon atoms to which they are attached is substituted by  $R^{16}$ ;

or two  $R^{10}$  groups on adjacent carbon ring atoms together form

$-N(R^{11})-C(O)-O-$ ,  $-N(R^{11})-C(O)-S-$ ,  $-(CH_2)_2CH(OR^{18})-$ ,  $-CH_2CH(OR^{18})CH_2-$ ,  
 5  $-(CH_2)_3CH(OR^{18})-$ ,  $-(CH_2)_2CH(OR^{18})CH_2-$ ,  $-(CH_2)_2C(O)-$ ,  $-CH_2C(O)CH_2-$ ,  $-(CH_2)_3C(O)-$ ,  
 $-(CH_2)_2C(O)CH_2-$ ,  $-O(CH_2)_2CH(OR^{18})-$  or  $-OCH_2CH(OR^{18})CH_2-$ , wherein the ring  
 formed by two  $R^{10}$  substituents and the ring carbon atoms to which they are attached  
 is optionally substituted on a carbon atom by hydroxyalkyl or alkoxyalkyl;

each  $R^{11}$  is independently selected from the group consisting of H and alkyl;

10 each  $R^{12}$  is independently selected from the group consisting of H, alkyl,  
 hydroxyalkyl, alkoxyalkyl,  $-C(O)-$ alkyl,  $-C(O)O-$ alkyl, (alkoxy)hydroxyalkyl, alkoxyalkyl-  
 $C(O)-$ ,  $-SO_2$ alkyl,  $-alkylene-C(O)alkyl$  and  $-alkylene-C(O)O-$ alkyl;

$R^{13}$  is H, alkyl or  $-CF_3$ ;

$R^{14}$  is H, alkyl, alkoxyalkyl, alkyl- $C(O)-$  or alkoxy- $C(O)-$ ;

15  $R^{15}$  is 1 to 3 substituents independently selected from the group consisting of  
 H, alkyl,  $-OH$ , alkoxy, alkoxyalkyl and hydroxyalkyl; or two  $R^{15}$  substituents, taken  
 together with the carbon to which they are both attached, form a  $-C(=O)-$  group;

$R^{16}$  is H, alkyl, alkoxyalkyl, OH or hydroxyalkyl;

$R^{17}$  is H or alkyl; and

20  $R^{18}$  is H or alkyl.

2. A compound of claim 1 wherein R is  $-C\equiv CR^6$ .

3. A compound of claim 2 wherein  $R^6$  is H or alkyl.

4. A compound of claim 1 wherein  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  are each H.

5. A compound of claim 1 wherein Z is  $R^{10}$ -aryl or  $R^{10}$ -heteroaryl.

6. A compound of claim 5 wherein Z is  $R^{10}$ -phenyl.

7. A compound of claim 6 wherein  $R^{10}$  is 1, 2 or 3 substituents independently  
 selected from the group consisting of H, halo,  $-C(O)R^{13}$ , alkyl, alkoxy, hydroxyalkyl,  
 (cycloalkyl)hydroxyalkyl, hydroxyalkoxy, alkoxyalkoxy, alkoxyalkyl, and cyanoalkyl.

8. A compound of claim 7 comprising two  $R^{10}$  substituents wherein one  $R^{10}$  is halo and the other  $R^{10}$  is halo,  $-C(O)R^{13}$ , alkyl, alkoxy, hydroxyalkyl, (cycloalkyl)hydroxyalkyl, hydroxyalkoxy, alkoxyalkoxy, alkoxyalkyl or cyanoalkyl.

5 9. A compound of claim 8 comprising two  $R^{10}$  substituents wherein one  $R^{10}$  is  $\alpha$ -fluoro and the other  $R^{10}$  is halo,  $-C(O)R^{13}$ , alkyl, alkoxy, hydroxyalkyl, (cycloalkyl)hydroxyalkyl, hydroxyalkoxy, alkoxyalkoxy, alkoxyalkyl or cyanoalkyl.

10. A compound of claim 5 wherein Z is  $R^{10}$ -heteroaryl.

10

11. A compound of claim 10 wherein Z is  $R^{10}$ -benzoxazolyl or  $R^{10}$ -benzisoxazolyl and  $R^{10}$  is 1 or 2 substituents independently selected from the group consisting of H, halo and alkyl.


15 12. A compound of claim 11 wherein one  $R^{10}$  is fluoro and one  $R^{10}$  is methyl.

13. A compound of claim 1 wherein R is  $-C\equiv CR^6$ ,  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  are each H, and Z is  $R^{10}$ -aryl or  $R^{10}$ -heteroaryl.


20 14. A compound of claim 13 wherein Z is  $R^{10}$ -phenyl and  $R^{10}$  is two substituents wherein one  $R^{10}$  is halo and the other  $R^{10}$  is halo,  $-C(O)R^{13}$ , alkyl, alkoxy, hydroxyalkyl, (cycloalkyl)hydroxyalkyl, hydroxyalkoxy, alkoxyalkoxy, alkoxyalkyl or cyanoalkyl.

25 15. A compound of claim 13 wherein Z is  $R^{10}$ -benzoxazolyl or  $R^{10}$ -benzisoxazolyl and  $R^{10}$  is 1 or 2 substituents independently selected from the group consisting of H, halo and alkyl.

16. A compound of claim 1 selected from the group consisting of



30



17. A pharmaceutical composition comprising a therapeutically effective amount of  
 10 a compound of claim 1 in a pharmaceutically acceptable carrier.

18. A method of treating central nervous system diseases or stroke, comprising  
 administering an effective amount of a compound of formula I to a mammal in need  
 of such treatment.

19. A method of claim 18 for treating depression, cognitive diseases and  
 neurodegenerative diseases.

20. A method of claim 18 for treating Parkinson's disease, senile dementia, psychoses of organic origin, attention deficit disorder, Extra Pyramidal Syndrome, dystonia, restless leg syndrome or periodic limb movement in sleep.

5 21. A pharmaceutical composition comprising a therapeutically effective amount of a combination of a compound of claim 1, and 1 to 3 other agents useful in treating Parkinson's disease in a pharmaceutically acceptable carrier.

10 22. A method of treating Parkinson's disease comprising administering to a mammal in need of such treatment an effective amount of a combination of a compound of claim 1, and 1 to 3 other agents useful in treating Parkinson's disease.

15 23. The method of claim 22 wherein the other agents are selected from the group consisting of L-DOPA, dopaminergic agonists, MAO-B inhibitors, DOPA decarboxylase inhibitors and COMT inhibitors.